The ongoing legal battle over mifepristone access has led to significant changes in abortion protocols across the United States. This situation affects millions, as mifepristone is used in about 60% of abortions nationwide.
In April 2021, the FDA lifted the in-person dispensing requirement for mifepristone due to the Covid-19 pandemic. In a surprising turn, this requirement was permanently lifted in 2023. Yet, recent court rulings have thrown this progress into disarray.
The Fifth Circuit Court of Appeals issued a stay that blocks the use of mifepristone, directly impacting its availability. U.S. District Judge Matthew Kacsmaryk suspended the FDA’s approval of mifepristone, leading to confusion and upheaval in medical practices.
As a response, organizations like Planned Parenthood are adapting. Nicole Clegg, President and CEO of Planned Parenthood of Northern New England, remarked on their strategy: “We closely monitored this court case, and we identified a way to keep telehealth medication abortion access intact for our patients.” They plan to switch to misoprostol-only for telehealth patients.
This legal turmoil stems from a lawsuit filed by individual doctors and medical groups opposed to abortion. The FDA and several leading medical groups argue that mifepristone is safe and effective. However, the court’s decisions suggest otherwise.
Danco Laboratories and GenBioPro manufacture mifepristone, which is typically used alongside misoprostol for medication abortions. The combination has been standard practice since mifepristone’s approval back in 2000.
Now, with the legal landscape shifting rapidly—regulatory chaos looms. GenBioPro stated that “the order has unleashed regulatory chaos,” highlighting the immediate impact on healthcare providers.
The next significant legal ruling is expected in early 2024 concerning the case FDA v. Alliance for Hippocratic Medicine. Until then, uncertainty reigns over how these legal battles will shape abortion access moving forward.
